Induced pluripotent stem cells (iPSCs) are among the most transformative innovations in modern regenerative medicine. The concept itself seems almost futuristic: by taking a small sample of somatic cells, such as skin fibroblasts, and reprogramming them back into a pluripotent state. These reprogrammed cells can give rise to diverse cell types, opening new possibilities for personalized medicine, disease modelling, and tissue regeneration.

However, with all the excitement comes a fair share of myths and misconceptions. Let’s separate the hype from the reality and debunk the top five myths about iPSCs.

Myth 1: “iPSCs are just like embryonic stem cells (ESCs) in every way.”

This is the most common point of confusion, and it’s easy to see why. While iPSCs share many key features with embryonic stem cells (for instance, pluripotency and self-renewal), they are not identical, and there are important differences in behavior, maturity, epigenetic state, and functionality.

The Debunk: The key difference isn’t what they can do, but where they come from. iPSCs are reprogrammed from somatic (adult) cells but may retain “epigenetic memory” of their origin, which can influence differentiation outcomes. [1]

  • Many studies point out that iPSC-derived cells often appear developmentally immature compared to their in vivo counterparts or the cells derived from ESCs [2].

  • Thus, assuming equivalence with ESCs (for all applications) may mislead researchers who still need to look closely at line quality, differentiation state, and functional endpoints.

Myth 2: “iPSCs have no ethical issues — they’re the perfect ethical alternative to embryonic stem cells.”

The Debunk: It’s true that iPSCs sidestep many of the ethical controversies tied to ESCs (such as embryo destruction). However, iPSC technology brings its own ethical, legal, and social implications, which must not be overlooked.

  • Ethical concerns include human–animal chimeras, generation of human gametes from iPSCs, consent for donor cells, and regulatory frameworks. [3]

  • Legal and social issues such as cell line ownership, intellectual property, equitable access, and standardization persist [4].

  • So yes, iPSCs reduce certain controversies, but they do not eliminate all ethical or governance challenges.

Myth 3: “iPSCs are too dangerous and will always cause tumours.”

The Debunk: This myth is born from a real scientific challenge, but it misrepresents the solution. The challenge is that pluripotency is a double-edged sword. If you inject undifferentiated iPSCs directly into a patient, their powerful growth capacity can cause them to form tumors called teratomas [5].

The scientific reality is a careful, multi-step process:

  1. Reprogramming: Create the iPSCs from the patient’s cells.

  2. Differentiation: Guide those iPSCs in a lab dish to become the exact cell type needed (e.g., retinal cells, heart muscle cells).

  3. Purification: Use advanced techniques to ensure that the final batch of cells contains only the desired, fully differentiated cells, removing any lingering iPSCs.

  4. Transplantation: Only these safe, purified cells are given to the patient.

This “differentiation-first” approach is the standard for all clinical applications and is a cornerstone of iPSC safety protocols [6].

Myth 4: “iPSC-based cures for everything are just around the corner.”

This myth confuses two very different applications: Disease modelling and regenerative therapy. The promise of iPSCs in regenerative medicine is enormous. However, while progress has been incredibly fast, we are still in the early days of this medical revolution. The timeline, complexity, and remaining hurdles mean that routine, broad-organ regeneration is not around the corner yet.

The Debunk: Here is a breakdown of the key scientific challenges that must be overcome for in vivo (therapeutic) applications.

Genetic and Epigenetic Instability:

 The reprogramming process itself, as well as the subsequent rapid cell culture, can introduce genetic and epigenetic abnormalities from small point mutations to large-scale chromosomal changes. from point mutations to large-scale chromosomal changes. This creates significant safety and quality-control barriers, as a single abnormal cell could compromise an entire batch [7]. High variability from line to line and batch to batch also remains a major challenge for standardization [8].

The Cellular Maturity Barrier:

A significant hurdle is that iPSC-derived cells are often functionally immature, resembling fetal or neonatal cells rather than adult ones. For example, iPSC-derived cardiomyocytes (heart cells) may have immature electrical signaling, which can cause fatal arrhythmias in animal models [9]. This maturity gap is a common problem across many cell types (e.g., liver and nerve cells), limiting their ability to safely integrate and function in a patient.

Clinical Trial Realities:

Pioneering clinical trials, like the one in Japan for macular degeneration, highlight the extreme complexity. These first-in-human trials are highly controlled, expensive, and prioritize safety. In fact, that trial was temporarily halted after genetic abnormalities were detected in one patient’s iPSC line before transplantation [10]. This event shows that safety protocols work, but it also proves that genomic instability is a real-time barrier and the process is far from routine.

 The promise of regenerative therapy is real, but it is a long-term scientific endeavor, not an overnight magic wand.

Myth 5: “Any lab can generate high-quality iPSC lines easily and reproducibly.”

Generating truly high-quality, well-characterized iPSC lines that can robustly differentiate and behave predictably is non-trivial. It involves expertise, rigorous QC, and attention to subtle variables.

Debunk:

  • Reprogramming efficiency can be very low depending on cell type, method, and culture conditions [11].

  • Genetic and epigenetic aberrations (including copy-number changes, point mutations, and mtDNA variants) have been reported in iPSCs and iPSC-derived cells [12] & [13].

  • The literature emphasizes the need for standardization, robust characterization, and treating iPSCs as a class of tools that require professional handling — not a plug-and-play cell line. [14] & [15]

Wrap Up

Induced pluripotent stem cells (iPSCs) are a powerful technology, offering unique ways to create patient-specific cell models for disease research and holding great promise for future regenerative therapies.

However, successfully using iPSC technology for reliable and accurate results requires addressing several key technical hurdles. The success of any iPSC-based project depends on four crucial factors:

  • Cell Line Quality: The genetic stability and overall health of the starting iPSC lines.

  • Cellular Maturity: Ensuring the iPSCs are properly differentiated into specialized cells (like heart or brain cells) that function as they would in the human body.

  • Rigorous Quality Control: Applying strict testing and validation standards at every stage of the workflow.

  • Model Suitability: Carefully matching the final cell model to the specific research question or application.

Reprocell provides the specialized scientific support and services to navigate these exact challenges, offering a robust portfolio of custom clinical-grade lines, high-quality research-grade iPSCs, and premium supporting reagents’

We invite researchers and industry partners to explore how we can help accelerate your stem cell research. 

Stem Cell Reagents and Products for Researchers in India.

References

  1. Jung Y, Bauer G, Nolta JA. Concise review: Induced pluripotent stem cell-derived mesenchymal stem cells: progress toward safe clinical products. Stem Cells. 2012 Jan;30(1):42-7. doi: 10.1002/stem.727. PMID: 21898694; PMCID: PMC3784250.
  1. Thiab, Sama, Juberiya M. Azeez, Alekya Anala, Moksha Nanda, Somieya Khan, Alexandra E. Butler, and Manjula Nandakumar. 2025. “Human-Induced Pluripotent Stem Cells (iPSCs) for Disease Modeling and Insulin Target Cell Regeneration in the Treatment of Insulin Resistance: A Review” Cells 14, no. 15: 1188. https://doi.org/10.3390/cells14151188
  2. Moradi S, Mahdizadeh H, Šarić T, Kim J, Harati J, Shahsavarani H, Greber B, Moore JB 4th. Research and therapy with induced pluripotent stem cells (iPSCs): social, legal, and ethical considerations. Stem Cell Res Ther. 2019 Nov 21;10(1):341. doi: 10.1186/s13287-019-1455-y. PMID: 31753034; PMCID: PMC6873767.
  3. Moradi S, Mahdizadeh H, Šarić T, Kim J, Harati J, Shahsavarani H, Greber B, Moore JB 4th. Research and therapy with induced pluripotent stem cells (iPSCs): social, legal, and ethical considerations. Stem Cell Res Ther. 2019 Nov 21;10(1):341. doi: 10.1186/s13287-019-1455-y. PMID: 31753034; PMCID: PMC6873767.
  4. Ben-David U, Benvenisty N. The tumorigenicity of human embryonic and induced pluripotent stem cells. Nat Rev Cancer. 2011 Apr;11(4):268-77. doi: 10.1038/nrc3034. Epub 2011 Mar 10. PMID: 21390058.
  5. Yamanaka S. Pluripotent Stem Cell-Based Cell Therapy-Promise and Challenges. Cell Stem Cell. 2020 Oct 1;27(4):523-531. doi: 10.1016/j.stem.2020.09.014. PMID: 33007237.
  6. Dhaiban S, Chandran S, Noshi M, Sajini AA. Clinical translation of human iPSC technologies: advances, safety concerns, and future directions. Front Cell Dev Biol. 2025 Sep 22;13:1627149. doi: 10.3389/fcell.2025.1627149. PMID: 41059336; PMCID: PMC12498231.
  7. Aboul-Soud, M. A. M., Alzahrani, A. J., & Mahmoud, A. (2021). Induced Pluripotent Stem Cells (iPSCs)—Roles in Regenerative Therapies, Disease Modelling and Drug Screening. Cells, 10(9), 2319. https://doi.org/10.3390/cells10092319 “Current Challenges of iPSC-Based Disease Modeling and Therapeutic Implications” — Cells/MDPI.
  8. Wu P, Deng G, Sai X, Guo H, Huang H, Zhu P. Maturation strategies and limitations of induced pluripotent stem cell-derived cardiomyocytes. Biosci Rep. 2021 Jun 25;41(6):BSR20200833. doi: 10.1042/BSR20200833. PMID: 33057659; PMCID: PMC8209171.
  9. Mandai M, Watanabe A, Kurimoto Y, Hirami Y, Morinaga C, Daimon T, Fujihara M, Akimaru H, Sakai N, Shibata Y, Terada M, Nomiya Y, Tanishima S, Nakamura M, Kamao H, Sugita S, Onishi A, Ito T, Fujita K, Kawamata S, Go MJ, Shinohara C, Hata KI, Sawada M, Yamamoto M, Ohta S, Ohara Y, Yoshida K, Kuwahara J, Kitano Y, Amano N, Umekage M, Kitaoka F, Tanaka A, Okada C, Takasu N, Ogawa S, Yamanaka S, Takahashi M. Autologous Induced Stem-Cell-Derived Retinal Cells for Macular Degeneration. N Engl J Med. 2017 Mar 16;376(11):1038-1046. doi: 10.1056/NEJMoa1608368. PMID: 28296613.
  10. Omole AE, Fakoya AOJ. Ten years of progress and promise of induced pluripotent stem cells: historical origins, characteristics, mechanisms, limitations, and potential applications. PeerJ. 2018 May 11;6:e4370. doi: 10.7717/peerj.4370. PMID: 29770269; PMCID: PMC5951134.
  11. Hussein, S., Batada, N., Vuoristo, S. et al. Copy number variation and selection during reprogramming to pluripotency. Nature 471, 58–62 (2011). https://doi.org/10.1038/nature09871
  12. Prigione A, Lichtner B, Kuhl H, Struys EA, Wamelink M, Lehrach H, Ralser M, Timmermann B, Adjaye J. Human induced pluripotent stem cells harbor homoplasmic and heteroplasmic mitochondrial DNA mutations while maintaining human embryonic stem cell-like metabolic reprogramming. Stem Cells. 2011 Sep;29(9):1338-48. doi: 10.1002/stem.683. PMID: 21732474.
  13. International Stem Cell Initiative. Assessment of established techniques to determine developmental and malignant potential of human pluripotent stem cells. Nat Commun. 2018 May 15;9(1):1925. doi: 10.1038/s41467-018-04011-3. PMID: 29765017; PMCID: PMC5954055.
  14. Sullivan S, Stacey GN, Akazawa C, Aoyama N, Baptista R, Bedford P, Bennaceur Griscelli A, Chandra A, Elwood N, Girard M, Kawamata S, Hanatani T, Latsis T, Lin S, Ludwig TE, Malygina T, Mack A, Mountford JC, Noggle S, Pereira LV, Price J, Sheldon M, Srivastava A, Stachelscheid H, Velayudhan SR, Ward NJ, Turner ML, Barry J, Song J. Quality control guidelines for clinical-grade human induced pluripotent stem cell lines. Regen Med. 2018 Oct;13(7):859-866. doi: 10.2217/rme-2018-0095. Epub 2018 Sep 12. PMID: 30205750.

Author

Swati Shukla

Scientific Sales Associate ( Stem Cells )